Wakefield Asset Management LLLP purchased a new position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 23,611 shares of the company's stock, valued at approximately $1,051,000. Wakefield Asset Management LLLP owned 0.05% of Omnicell as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Creative Planning grew its holdings in shares of Omnicell by 23.1% during the 3rd quarter. Creative Planning now owns 11,667 shares of the company's stock worth $509,000 after acquiring an additional 2,188 shares during the period. Roubaix Capital LLC bought a new stake in shares of Omnicell during the third quarter valued at approximately $1,851,000. 1620 Investment Advisors Inc. grew its stake in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company's stock worth $96,000 after purchasing an additional 1,542 shares during the period. Rice Hall James & Associates LLC bought a new position in Omnicell in the third quarter worth $2,723,000. Finally, QRG Capital Management Inc. purchased a new position in Omnicell during the third quarter valued at $231,000. 97.70% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on OMCL shares. JPMorgan Chase & Co. raised their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research note on Thursday, November 21st. StockNews.com lowered Omnicell from a "buy" rating to a "hold" rating in a research report on Tuesday, December 10th. Bank of America cut their target price on Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a research note on Monday, January 6th. Benchmark reiterated a "buy" rating and issued a $62.00 price target on shares of Omnicell in a research note on Tuesday, February 4th. Finally, Wells Fargo & Company cut their price objective on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $52.33.
View Our Latest Report on Omnicell
Insider Activity
In related news, Director Mark W. Parrish sold 12,000 shares of the stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares of the company's stock, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 2.64% of the company's stock.
Omnicell Stock Performance
OMCL stock traded down $0.31 on Tuesday, hitting $37.42. The company had a trading volume of 456,031 shares, compared to its average volume of 491,903. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of 138.79, a P/E/G ratio of 7.53 and a beta of 0.78. The company has a current ratio of 1.37, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13. The stock's 50-day simple moving average is $42.26 and its 200 day simple moving average is $43.79. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $55.75.
Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. As a group, equities research analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.
About Omnicell
(
Free Report)
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
See Also
Before you consider Omnicell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Omnicell wasn't on the list.
While Omnicell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
